Related Experiment Video
Updated: May 9, 2025
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Managing Coagulation Using the Sonoclot Analyzer in Patients With Disseminated Intravascular Coagulation
1Peng Wan is a chief physician, Department of Critical Care Unit, First Clinical Medical College of Three Gorges University, Yichang, Hubei, China.
Insights
The Sonoclot analyzer improved 30-day survival rates for disseminated intravascular coagulation (DIC) patients. This tool also reduced anticoagulation and transfusion needs, especially in sepsis and heatstroke cases.
Area of Science:
- Critical Care Medicine
- Hematology
- Medical Diagnostics
Background:
- Disseminated intravascular coagulation (DIC) management lacks proven outcome-improving tools.
- Evidence supporting the Sonoclot analyzer's clinical utility in DIC is limited.
Purpose of the Study:
- To assess the effectiveness of a Sonoclot analyzer-based algorithm in enhancing short-term prognosis for DIC patients.
- To compare clinical outcomes between a Sonoclot-guided approach and conventional coagulation assays.
Main Methods:
- A prospective study involving 279 patients with overt DIC, divided into conventional coagulation assay (CCA) and Sonoclot groups.
- Data on anticoagulation, transfusions, and 30-day survival were collected and analyzed post-algorithm implementation.
- Comparison of survival rates and resource utilization between the two groups.
Main Results:
- The Sonoclot group demonstrated a significantly higher 30-day survival rate (78.45%) compared to the CCA group (63.64%; P = .02).
- Heparin dosage, anticoagulation duration, and major bleeding rates were significantly lower in the Sonoclot group (P < .001).
- Transfusion requirements (fresh frozen plasma, platelets, cryoprecipitate) were substantially reduced in the Sonoclot group (P ≤ .03).
Conclusions:
- The Sonoclot analyzer shows potential as a valuable tool for guiding coagulation management in DIC.
- A Sonoclot-based algorithm may improve clinical outcomes, particularly for DIC patients with moderately severe sepsis or heatstroke.
Background:
Evidence for the effectiveness of the Sonoclot analyzer in improving clinical outcomes in disseminated intravascular coagulation (DIC) is lacking.
Objective:
To evaluate the effectiveness of an algorithm based on the Sonoclot analyzer in improving the short-term prognosis of patients with DIC.
Methods:
A total of 279 patients with overt DIC who were admitted to the hospital within 18 months before and after implementation of the new Sonoclot-based algorithm were enrolled in the study. They were assigned to either a conventional coagulation assay (CCA) group (n = 148) or a Sonoclot group (n = 131). Data associated with anti-coagulation and transfusion were collected and analyzed. The 30-day survival rate after hospital admission was compared between groups.
Results:
The Sonoclot group had a higher 30-day survival rate than the CCA group (78.45% vs 63.64%; P = .02). The heparin dose, anticoagulation course, and major bleeding rate were significantly reduced in the Sonoclot group compared with the CCA group for all patients and for patients undergoing continuous renal replacement therapy (all P < .001). Fresh frozen plasma, platelet, and cryoprecipitate requirements were substantially lower in the Sonoclot group than in the CCA group (P = .007, .03, and .02, respectively). In a stratified analysis, improved survival rate was seen mainly in patients with moderately severe sepsis and heatstroke, with an Acute Physiology and Chronic Health Evaluation II score of 20 to 29.
Conclusion:
The Sonoclot analyzer may be useful to guide coagulation management in patients with DIC. Use of the Sonoclot-based algorithm may improve outcomes for DIC patients with moderately severe sepsis or heatstroke.
More Related Videos
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:09Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
01:24Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:16Clot Retraction and Fibrinolysis
01:05Introduction to Hemostasis
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...